NSAID Safety Guidelines

Save

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complica

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Save

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA).

Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?

Save

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Save

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

Save

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots

Save

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Save

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axi

Upadacitinib Effective in Ankylosing Spondylitis

Save

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Variations in First Biologic Use in Rheumatoid Arthritis

Save

A Canadian analysis shows that rheumatoid arthritis (RA) patients are more likely to receive biologic DMARDs earlier if they are younger, female, and living in urban areas closer to prescribers.

Secukinumab Improves Enthesitis

Save

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

Spondyloarthritis Affects Pregnancy Outcomes

Save

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

IL-17 Inhibitors In Non-Radiographic Axial SpA

Save

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Save

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

Psoriatic Arthritis at ACR 2019

Save

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

Muscle Loss and Frailty in Rheumatic Disease

Save

At the 2019 ACR annual meeting, several abstracts looked at the importance of myopia (muscle wasting due to illness at any age) and sarcopenia (age related muscle wasting) in the setting of various rheumatologic diseases.

ACR 2019 – Best of the Plenary Sessions

Save

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

ACR 2019 - Report from Day One (Sunday)

Save

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis